Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

Trial Details

NCT ID
NCT03297606
Phase
PHASE2
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Olaparib
  • Dasatinib
  • Nivolumab plus Ipilimumab
  • Axitinib
  • Bosutinib
  • Crizotinib
Locations (sample)
  • Edmonton, Alberta, Canada|53.55014,-113.46871
  • Kelowna, British Columbia, Canada|49.88307,-119.48568
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Kingston, Ontario, Canada|44.22976,-76.48098
  • London, Ontario, Canada|42.98339,-81.23304

Key Eligibility Criteria

  • Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid tumour (excluding primary brain tumours), multiple myeloma or B ce…
  • ECOG performance status 0-2.
  • Patients must have normal organ function as follows:
  • Absolute neutrophil count: ≥ 1.5 x 10\^9/L for solid tumours; ≥ 1.0 x 10\^9/L for neurologic malignancies

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →